Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.
References
Mai, H.Q. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01444-0 (2021).
Yang, Y. et al. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00302-8 (2021)
BeiGene. https://ir.beigene.com/news-details/?id=29e026ba-7774-40a1-81f6-41d2321f1845 (21 May 2021).
Wong, K.C.W. et al. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-021-00524-x (2021).
GLOBOCAN. World Health Organization https://gco.iarc.fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.pdf 2020:
Wang, F. H. et al. J. Clin. Oncol. 39, 704–712 (2021).
Zhang, L. et al. Lancet 388, 1883–1892 (2016).
Sun, L. T. et al. Sci. Rep. 10, 2083 (2020).
Gandhi, L. et al. N. Engl. J. Med. 378, 2078–2092 (2018).
Paz-Ares, L. et al. N. Engl. J. Med. 379, 2040–2051 (2018).
Le, Q. T. et al. J. Natl. Cancer Inst. 111, 655–663 (2019).
Yu, J. X. et al. Nat. Rev. Drug Discov. 19, 163–164 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.B.Y.M. is an advisory board member and receives speaker’s honoraria from Bristol Myers Squibb, Merck Serono, Merck Sharpe & Dohme (MSD) and Novartis, and is a consultant for Y-Biologics and Viracta Therapeutics. E.P.H. has received speaker’s honoraria from Merck Serono and MSD, and is a consultant and advisory board member for MSD. A.T.C.C. receives research funding from Merck Serono, MSD and Pfizer, and is an advisory board member for MSD and Tessa Therapeutics.
Rights and permissions
About this article
Cite this article
Ma, B.B.Y., Hui, E.P. & Chan, A.T.C. The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nat Med 27, 1512–1513 (2021). https://doi.org/10.1038/s41591-021-01482-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01482-8
- Springer Nature America, Inc.